Summit Therapeutics says PhaseOut DMD clinical trial did not meet primary endpoint
The AIM-listed pharmaceuticals group said that because of the outcome, it is discontinuing its development of ezutromid and as a…
The AIM-listed pharmaceuticals group said that because of the outcome, it is discontinuing its development of ezutromid and as a…